首页 > 最新文献

Acta clinica Croatica最新文献

英文 中文
CRUSH SYNDROME IN EARTHQUAKES - STAY AND PLAY OR LOAD AND GO? 地震中的挤压综合征--留着玩还是装上就走?
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.24
Iskra Alexandra Nola, Matija Dvorski, Mirza Žižak, Tomislav Kuliš

Earthquakes are unpredictable natural disasters accompanied by material damage and many victims. In the case of a person remaining trapped under the collapsed material, the development of crush syndrome can occur. Crush syndrome is the result of traumatic rhabdomyolysis and is present in 2%-15% of all injured persons in an earthquake. It is not easy to recognize, and proper treatment is challenging. Persons who have a clear crush injury and/or have been immobilized for more than four hours should be considered potential victims of crush syndrome. Therefore, knowledge about crush syndrome must be comprehensive and accessible to all parties involved. In this paper, the management of crush syndrome victims, which includes the principles of triage, and medical and logistic principles as well, is presented. Triage principles are presented at the level of triage priorities, places, and diagnoses. Medical principles, crucial for crush syndrome, are presented regarding the duration of compression and time before or after extraction of the patient. Logistic principles provide an overview of the priorities and modes of transport in relation to distance of health institutions, and the importance of management and education associated with crush syndrome. Each country with recognized disasters (natural or man-made) in which crush-related victims are expected, will benefit if the knowledge about triage, medical and logistic principles for crush syndrome is incorporated in their educational programs and regularly updated.

地震是不可预测的自然灾害,伴随着物质损失和众多受害者。如果有人仍被困在坍塌的物质下,就可能发生挤压综合征。挤压综合征是外伤性横纹肌溶解症的结果,在地震中的所有伤员中,2%-15% 会出现这种症状。这种疾病不易识别,正确治疗也很困难。有明显挤压伤和/或固定时间超过四小时的人员应被视为挤压综合征的潜在受害者。因此,有关挤压综合征的知识必须全面,并让所有相关人员都能了解。本文介绍了挤压综合征患者的处理方法,包括分流原则以及医疗和后勤原则。本文从分流的优先次序、地点和诊断等层面介绍了分流原则。医疗原则对挤压综合症至关重要,介绍了挤压持续时间和救出病人前后的时间。后勤原则概述了与医疗机构距离有关的优先事项和运输方式,以及与挤压综合症有关的管理和教育的重要性。如果将挤压综合症的分诊、医疗和后勤原则知识纳入教育计划并定期更新,那么每个发生公认灾难(自然或人为)并预计会有挤压相关受害者的国家都将从中受益。
{"title":"CRUSH SYNDROME IN EARTHQUAKES - STAY AND PLAY OR LOAD AND GO?","authors":"Iskra Alexandra Nola, Matija Dvorski, Mirza Žižak, Tomislav Kuliš","doi":"10.20471/acc.2023.62.s2.24","DOIUrl":"10.20471/acc.2023.62.s2.24","url":null,"abstract":"<p><p>Earthquakes are unpredictable natural disasters accompanied by material damage and many victims. In the case of a person remaining trapped under the collapsed material, the development of crush syndrome can occur. Crush syndrome is the result of traumatic rhabdomyolysis and is present in 2%-15% of all injured persons in an earthquake. It is not easy to recognize, and proper treatment is challenging. Persons who have a clear crush injury and/or have been immobilized for more than four hours should be considered potential victims of crush syndrome. Therefore, knowledge about crush syndrome must be comprehensive and accessible to all parties involved. In this paper, the management of crush syndrome victims, which includes the principles of triage, and medical and logistic principles as well, is presented. Triage principles are presented at the level of triage priorities, places, and diagnoses. Medical principles, crucial for crush syndrome, are presented regarding the duration of compression and time before or after extraction of the patient. Logistic principles provide an overview of the priorities and modes of transport in relation to distance of health institutions, and the importance of management and education associated with crush syndrome. Each country with recognized disasters (natural or man-made) in which crush-related victims are expected, will benefit if the knowledge about triage, medical and logistic principles for crush syndrome is incorporated in their educational programs and regularly updated.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"158-165"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
REVIEW OF ADVERSE DRUG REACTIONS OF MEDICINES USED FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA REPORTED TO HALMED. 回顾向 halmed 报告的治疗良性前列腺增生症的药物不良反应。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.10
Iva Kuliš, Željana Margan Koletić, Tvrtko Hudolin, Siniša Tomić

Benign prostatic hyperplasia is one of the most common diseases in men, with a prevalence rate of 50% in their 50s to 80% in their 80s, and is mostly treated with chronic drug therapy. The aim of this study was to analyze adverse drug reactions (ADR) to drugs used in benign prostate hyperplasia (BPH) treatment reported to HALMED from 2008 to 2021. Data on ADR reports in Croatia were obtained from the VigiFlow national database and on the use of drugs for BPH in Croatia from Drug Utilization Reports from HALMED. In the observed period, the number of reports on each BPH drug, total number of reports, seriousness of reported ADR, patient age and sex, type of reporter, and most reported ADRs were analyzed. Results showed that 438 ADR reports were received, of which 45.95% on tamsulosin as the most frequently used drug for BPH. Of all reports, 84% were non-serious, 96% were reported in men and 82% in patients older than 45 years. The most frequently reported ADRs were consistent with the known safety profile of BPH drugs. Pharmacists were the most common (47%) reporters of ADRs for BPH drugs, while 33% were reported by physicians. Analysis of the reported ADRs showed that most frequently reported ones were in line with the known safety profile of BPH drugs. However, given the prevalence of the disease and the extent of the use of BPH drugs, it could be argued that the number of reports could be higher (i.e., 34 reports/year). Reporting on ADRs is necessary to better understand the safety profile of drugs in the post-authorization period, and more information on the safe use of medicines could be collected by raising awareness of healthcare professionals.

良性前列腺增生是男性最常见的疾病之一,发病率从50多岁的50%到80多岁的80%不等,大多采用慢性药物治疗。本研究旨在分析2008年至2021年向HALMED报告的良性前列腺增生(BPH)治疗药物的不良反应(ADR)。克罗地亚的药物不良反应报告数据来自 VigiFlow 国家数据库,克罗地亚良性前列腺增生症治疗药物的使用数据来自 HALMED 的药物使用报告。在观察期内,对每种良性前列腺增生症药物的报告数量、报告总数、报告的不良反应严重程度、患者年龄和性别、报告人类型以及报告最多的不良反应进行了分析。结果显示,共收到 438 份不良反应报告,其中 45.95% 涉及坦索罗辛,是治疗良性前列腺增生症最常用的药物。在所有报告中,84%为非严重不良反应,96%为男性,82%为45岁以上患者。最常报告的不良反应与前列腺增生症药物的已知安全性相符。药剂师是最常见的良性前列腺增生症药物不良反应报告者(47%),而医生报告的不良反应占 33%。对所报告的不良反应进行的分析表明,最常报告的不良反应与前列腺增生症药物的已知安全性相符。然而,鉴于该疾病的发病率和良性前列腺增生症药物的使用范围,可以说报告的数量可能更高(即每年 34 例)。为了更好地了解药物在获得授权后的安全状况,有必要报告药物不良反应,并且可以通过提高医护人员的意识来收集更多关于安全用药的信息。
{"title":"REVIEW OF ADVERSE DRUG REACTIONS OF MEDICINES USED FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA REPORTED TO HALMED.","authors":"Iva Kuliš, Željana Margan Koletić, Tvrtko Hudolin, Siniša Tomić","doi":"10.20471/acc.2023.62.s2.10","DOIUrl":"10.20471/acc.2023.62.s2.10","url":null,"abstract":"<p><p>Benign prostatic hyperplasia is one of the most common diseases in men, with a prevalence rate of 50% in their 50s to 80% in their 80s, and is mostly treated with chronic drug therapy. The aim of this study was to analyze adverse drug reactions (ADR) to drugs used in benign prostate hyperplasia (BPH) treatment reported to HALMED from 2008 to 2021. Data on ADR reports in Croatia were obtained from the VigiFlow national database and on the use of drugs for BPH in Croatia from Drug Utilization Reports from HALMED. In the observed period, the number of reports on each BPH drug, total number of reports, seriousness of reported ADR, patient age and sex, type of reporter, and most reported ADRs were analyzed. Results showed that 438 ADR reports were received, of which 45.95% on tamsulosin as the most frequently used drug for BPH. Of all reports, 84% were non-serious, 96% were reported in men and 82% in patients older than 45 years. The most frequently reported ADRs were consistent with the known safety profile of BPH drugs. Pharmacists were the most common (47%) reporters of ADRs for BPH drugs, while 33% were reported by physicians. Analysis of the reported ADRs showed that most frequently reported ones were in line with the known safety profile of BPH drugs. However, given the prevalence of the disease and the extent of the use of BPH drugs, it could be argued that the number of reports could be higher (i.e., 34 reports/year). Reporting on ADRs is necessary to better understand the safety profile of drugs in the post-authorization period, and more information on the safe use of medicines could be collected by raising awareness of healthcare professionals.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"68-75"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PERCUTANEOUS APPROACH TO THE KIDNEY: SIMILARITIES AND DIFFERENCES OF VARIOUS TECHNIQUES - EXPERIENCE IN OSIJEK UNIVERSITY HOSPITAL CENTER. 经皮肾脏路径:各种技术的异同--奥西耶克大学医院中心的经验。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.22
Mile Cvitković, Jakov Filipović, Josip Perković, Oliver Pavlović

Today, percutaneous nephrolithotomy (PCNL) is a standard procedure in the treatment of large kidney stones. Development of the procedure began in 1976 with publication of the first reports, while turning point came in 1985 when the first 250 cases were described. Subsequently, PCNL has become standard in the treatment of kidney stones instead of open surgery. Numerous modifications of the procedure have been developed with advancement of modern technology. Nevertheless, there is still the necessity for clearer understanding of differences and circumstances of choice among different techniques. There are significant differences in the instruments used for the procedure, so we distinguish standard PCNL (working channel of 24-30 Fr), mini PCNL (working channel of 11-18 Fr), ultra-mini PCNL (working channel <15 Fr), and micro PCNL (working channel <6 Fr). With the development of flexible ureteroscopy (FURS), a combined method is also being developed, i.e., Endoscopic Combined IntraRenal Surgery (ECIRS, PCNL + FURS). Furthermore, each procedure can be performed in prone or supine position. The aim of this paper is to point out the similarities and differences, the advantages and disadvantages of different techniques, with an additional aim to present our experience and current standard practice in kidney stone treatment.

如今,经皮肾镜取石术(PCNL)已成为治疗大块肾结石的标准手术。该手术的发展始于 1976 年,当时发表了第一份报告,而转折点出现在 1985 年,当时描述了第一批 250 个病例。随后,PCNL 成为治疗肾结石的标准方法,取代了开腹手术。随着现代技术的发展,该手术也进行了许多改进。尽管如此,仍有必要更清楚地了解不同技术之间的差异和选择情况。该手术使用的器械有很大不同,因此我们将其分为标准 PCNL(工作通道为 24-30 Fr)、迷你 PCNL(工作通道为 11-18 Fr)、超迷你 PCNL(工作通道为 24-30 Fr)和超迷你 PCNL(工作通道为 11-18 Fr)。
{"title":"PERCUTANEOUS APPROACH TO THE KIDNEY: SIMILARITIES AND DIFFERENCES OF VARIOUS TECHNIQUES - EXPERIENCE IN OSIJEK UNIVERSITY HOSPITAL CENTER.","authors":"Mile Cvitković, Jakov Filipović, Josip Perković, Oliver Pavlović","doi":"10.20471/acc.2023.62.s2.22","DOIUrl":"10.20471/acc.2023.62.s2.22","url":null,"abstract":"<p><p>Today, percutaneous nephrolithotomy (PCNL) is a standard procedure in the treatment of large kidney stones. Development of the procedure began in 1976 with publication of the first reports, while turning point came in 1985 when the first 250 cases were described. Subsequently, PCNL has become standard in the treatment of kidney stones instead of open surgery. Numerous modifications of the procedure have been developed with advancement of modern technology. Nevertheless, there is still the necessity for clearer understanding of differences and circumstances of choice among different techniques. There are significant differences in the instruments used for the procedure, so we distinguish standard PCNL (working channel of 24-30 Fr), mini PCNL (working channel of 11-18 Fr), ultra-mini PCNL (working channel <15 Fr), and micro PCNL (working channel <6 Fr). With the development of flexible ureteroscopy (FURS), a combined method is also being developed, i.e., Endoscopic Combined IntraRenal Surgery (ECIRS, PCNL + FURS). Furthermore, each procedure can be performed in prone or supine position. The aim of this paper is to point out the similarities and differences, the advantages and disadvantages of different techniques, with an additional aim to present our experience and current standard practice in kidney stone treatment.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"148-152"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
THULIUM:YAG LASER ENUCLEATION OF THE PROSTATE (ThuLEP) - OUR EXPERIENCE IN 246 PATIENTS. 铥钇钕激光前列腺电切术(ThuLEP)--我们在 246 例患者中的经验。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.14
Nikola Zebić, Velimir Terzić, Vinko Krajina

New minimally invasive procedures to treat benign prostatic hyperplasia (BPH) have been developed in the last 20 years. With the introduction of laser enucleation techniques in prostate surgery, previous standard surgical procedures (open retropubic or transvesical adenectomy and transurethral resection of the prostate) have become less relevant, especially in case of very large prostates. The objective of this paper is to describe the experience and results of thulium:YAG laser application in BPH treatment in our department. In the last five years, 246 patients underwent thulium:YAG laser enucleation of the prostate (ThuLEP) due to BPH or lower urinary tract symptoms following complete urologic evaluation. The mean age of our patients was 73 (range 51-95) years and mean duration of surgery was 92 minutes. The mean weight of enucleated tissue was 73 grams. A low rate of intraoperative and early postoperative complications and short length of stay proved minimal invasiveness of this procedure, which results in significant improvements in urodynamic parameters and substantially reduces the post-void residual urine volume. The most important surgical and technical characteristics (enucleation and low-power laser application) make ThuLEP a safe and efficient surgical method not limited by the prostate volume. ThuLEP has a potential to displace the current standard surgical procedures to treat BPH.

近 20 年来,治疗良性前列腺增生症(BPH)的新型微创手术不断发展。随着激光去核技术在前列腺手术中的应用,以前的标准手术方法(开放性耻骨后或经膀胱腺切除术和经尿道前列腺切除术)已变得不再适用,尤其是在前列腺体积非常大的情况下。本文旨在介绍我科应用铥:YAG 激光治疗良性前列腺增生症的经验和结果。在过去五年中,共有 246 名患者因前列腺增生症或下尿路症状接受了铥:YAG 激光前列腺去核术(ThuLEP),并进行了全面的泌尿系统评估。患者的平均年龄为 73 岁(51-95 岁不等),平均手术时间为 92 分钟。去核组织的平均重量为 73 克。术中和术后早期并发症发生率低,住院时间短,证明了这种手术的微创性,显著改善了尿动力学参数,大大减少了排尿后残余尿量。最重要的手术和技术特点(去核和低功率激光应用)使 ThuLEP 成为一种不受前列腺体积限制的安全高效的手术方法。ThuLEP 有可能取代目前治疗良性前列腺增生症的标准手术方法。
{"title":"THULIUM:YAG LASER ENUCLEATION OF THE PROSTATE (ThuLEP) - OUR EXPERIENCE IN 246 PATIENTS.","authors":"Nikola Zebić, Velimir Terzić, Vinko Krajina","doi":"10.20471/acc.2023.62.s2.14","DOIUrl":"10.20471/acc.2023.62.s2.14","url":null,"abstract":"<p><p>New minimally invasive procedures to treat benign prostatic hyperplasia (BPH) have been developed in the last 20 years. With the introduction of laser enucleation techniques in prostate surgery, previous standard surgical procedures (open retropubic or transvesical adenectomy and transurethral resection of the prostate) have become less relevant, especially in case of very large prostates. The objective of this paper is to describe the experience and results of thulium:YAG laser application in BPH treatment in our department. In the last five years, 246 patients underwent thulium:YAG laser enucleation of the prostate (ThuLEP) due to BPH or lower urinary tract symptoms following complete urologic evaluation. The mean age of our patients was 73 (range 51-95) years and mean duration of surgery was 92 minutes. The mean weight of enucleated tissue was 73 grams. A low rate of intraoperative and early postoperative complications and short length of stay proved minimal invasiveness of this procedure, which results in significant improvements in urodynamic parameters and substantially reduces the post-void residual urine volume. The most important surgical and technical characteristics (enucleation and low-power laser application) make ThuLEP a safe and efficient surgical method not limited by the prostate volume. ThuLEP has a potential to displace the current standard surgical procedures to treat BPH.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"104-109"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRENDS IN PROSTATE CANCER DIAGNOSIS DURING THE COVID-19 PANDEMIC: SINGLE-INSTITUTION EXPERIENCE. Covid-19大流行期间前列腺癌诊断的趋势:单一机构的经验。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.4
Ivona Ćudina, Marin Glavčić, Pero Hrabač, Stela Bulimbašić, Marijana Ćorić

The aim of this study was to compare the number of biopsy and surgical procedures on prostate, as well as the number of newly diagnosed, histologically confirmed cases of prostate cancer during the COVID-19 pandemic at Zagreb University Hospital Center (UHC). We retrospectively collected and processed a total of 1344 histopathologic findings of the prostate at the Zagreb UHC. Our results show that during the COVID-19 pandemic, there was a statistically significant decrease in the absolute number of biopsy and surgical procedures on prostate at Zagreb UHC, and so was the number of newly diagnosed, histologically confirmed cases of prostate cancer. During the observed time of the pandemic (March 19, 2020 to December 31, 2020), there was a 37.5% decrease in the absolute number of newly diagnosed prostate cancer cases compared to the same period of the previous year (March 19, 2019 to December 31, 2019). To our knowledge, this is the first study of this kind that is based on the number of prostate cancer diagnoses in Croatia. By observing the early period of the pandemic, our results provide important guidelines for monitoring and understanding the long-term consequences of the pandemic on the prostate cancer morbidity and mortality.

本研究旨在比较 COVID-19 大流行期间萨格勒布大学医院中心(UHC)前列腺活检和手术的数量,以及新诊断的、经组织学确诊的前列腺癌病例数量。我们回顾性地收集并处理了萨格勒布大学医院中心的 1344 例前列腺组织病理学检查结果。我们的研究结果表明,在 COVID-19 大流行期间,萨格勒布大学医疗中心前列腺活检和手术的绝对数量出现了统计学意义上的显著下降,新诊断的、组织学确诊的前列腺癌病例数量也出现了显著下降。在大流行病观察期间(2020 年 3 月 19 日至 2020 年 12 月 31 日),与上一年同期(2019 年 3 月 19 日至 2019 年 12 月 31 日)相比,新诊断的前列腺癌病例绝对数量减少了 37.5%。据我们所知,这是第一项基于克罗地亚前列腺癌诊断数量的此类研究。通过观察疫情初期的情况,我们的研究结果为监测和了解疫情对前列腺癌发病率和死亡率的长期影响提供了重要指导。
{"title":"TRENDS IN PROSTATE CANCER DIAGNOSIS DURING THE COVID-19 PANDEMIC: SINGLE-INSTITUTION EXPERIENCE.","authors":"Ivona Ćudina, Marin Glavčić, Pero Hrabač, Stela Bulimbašić, Marijana Ćorić","doi":"10.20471/acc.2023.62.s2.4","DOIUrl":"10.20471/acc.2023.62.s2.4","url":null,"abstract":"<p><p>The aim of this study was to compare the number of biopsy and surgical procedures on prostate, as well as the number of newly diagnosed, histologically confirmed cases of prostate cancer during the COVID-19 pandemic at Zagreb University Hospital Center (UHC). We retrospectively collected and processed a total of 1344 histopathologic findings of the prostate at the Zagreb UHC. Our results show that during the COVID-19 pandemic, there was a statistically significant decrease in the absolute number of biopsy and surgical procedures on prostate at Zagreb UHC, and so was the number of newly diagnosed, histologically confirmed cases of prostate cancer. During the observed time of the pandemic (March 19, 2020 to December 31, 2020), there was a 37.5% decrease in the absolute number of newly diagnosed prostate cancer cases compared to the same period of the previous year (March 19, 2019 to December 31, 2019). To our knowledge, this is the first study of this kind that is based on the number of prostate cancer diagnoses in Croatia. By observing the early period of the pandemic, our results provide important guidelines for monitoring and understanding the long-term consequences of the pandemic on the prostate cancer morbidity and mortality.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"28-32"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MANAGEMENT OF PROSTATE CANCER IN KIDNEY TRANSPLANT RECIPIENTS. 肾移植受者的前列腺癌管理。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.15
Zoran Zimak, Ivica Mokos, Hrvoje Saić, Dinko Hauptman, Milko Padovan, Tvrtko Hudolin, Eleonora Goluža, Nikolina Bašić Jukić, Željko Kaštelan

Kidney transplantation is the treatment of choice in eligible patients with end-stage kidney disease. Prostate cancer (PC) is the second most common cancer in men worldwide. The prevalence of chronic kidney disease worldwide is 13.4%. The management of localized PC in these patients is challenging due to immunosuppressive therapy and pelvic graft localization. High graft and recipient survival rates have resulted in higher numbers of these patients in our everyday practice. A retrospective analysis of male patients who had undergone kidney transplantation at our center between 2002 and 2022 and were diagnosed and treated for PC was performed. We analyzed the incidence, treatment methods, and follow-up of PC patients in this population. A total of 1079 male patients were transplanted. PC was diagnosed in 12 patients (8 after and 4 before transplantation). The incidence of PC was 1.11%. Radical prostatectomy was performed in 11 patients, and one patient was treated with radical radiotherapy. Eleven patients had stable graft function; 1 graftectomy was performed, unrelated to PC. Three patients were indicated for salvage radiotherapy, one is in process for prostate-specific membrane antigen positron emission tomography (PSMA PET CT), and 7 patients are in follow-up and without recurrence. Radical prostatectomy is a safe treatment method for localized PC in kidney transplant recipients, which does not impair graft function and survival.

肾移植是符合条件的终末期肾病患者的首选治疗方法。前列腺癌(PC)是全球男性第二大常见癌症。全球慢性肾病的发病率为 13.4%。由于免疫抑制治疗和盆腔移植物定位,对这些患者的局部前列腺癌治疗具有挑战性。由于移植物和受体的存活率较高,在我们的日常工作中,这类患者的数量也越来越多。我们对 2002 年至 2022 年期间在本中心接受肾移植手术并确诊和治疗 PC 的男性患者进行了回顾性分析。我们分析了这一人群中 PC 患者的发病率、治疗方法和随访情况。共有 1079 名男性患者接受了肾移植。12名患者(8名在移植后,4名在移植前)被确诊为PC。PC发病率为1.11%。11 名患者接受了根治性前列腺切除术,1 名患者接受了根治性放疗。11名患者的移植物功能稳定;1名患者接受了移植物切除术,但与PC无关。3 名患者需要进行挽救性放疗,1 名患者正在进行前列腺特异性膜抗原正电子发射断层扫描(PSMA PET CT),7 名患者正在接受随访,没有复发。根治性前列腺切除术是肾移植受者局部PC的一种安全治疗方法,不会损害移植物的功能和存活率。
{"title":"MANAGEMENT OF PROSTATE CANCER IN KIDNEY TRANSPLANT RECIPIENTS.","authors":"Zoran Zimak, Ivica Mokos, Hrvoje Saić, Dinko Hauptman, Milko Padovan, Tvrtko Hudolin, Eleonora Goluža, Nikolina Bašić Jukić, Željko Kaštelan","doi":"10.20471/acc.2023.62.s2.15","DOIUrl":"10.20471/acc.2023.62.s2.15","url":null,"abstract":"<p><p>Kidney transplantation is the treatment of choice in eligible patients with end-stage kidney disease. Prostate cancer (PC) is the second most common cancer in men worldwide. The prevalence of chronic kidney disease worldwide is 13.4%. The management of localized PC in these patients is challenging due to immunosuppressive therapy and pelvic graft localization. High graft and recipient survival rates have resulted in higher numbers of these patients in our everyday practice. A retrospective analysis of male patients who had undergone kidney transplantation at our center between 2002 and 2022 and were diagnosed and treated for PC was performed. We analyzed the incidence, treatment methods, and follow-up of PC patients in this population. A total of 1079 male patients were transplanted. PC was diagnosed in 12 patients (8 after and 4 before transplantation). The incidence of PC was 1.11%. Radical prostatectomy was performed in 11 patients, and one patient was treated with radical radiotherapy. Eleven patients had stable graft function; 1 graftectomy was performed, unrelated to PC. Three patients were indicated for salvage radiotherapy, one is in process for prostate-specific membrane antigen positron emission tomography (PSMA PET CT), and 7 patients are in follow-up and without recurrence. Radical prostatectomy is a safe treatment method for localized PC in kidney transplant recipients, which does not impair graft function and survival.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"110-113"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
POINT-OF-CARE DIAGNOSTIC APPROACH IN A CRITICALLY ILL PATIENT WITH SEVERE BLEEDING FROM URINARY TRACT. 对一名泌尿道严重出血的危重病人进行护理点诊断的方法。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.20
Sonja Škiljić, Nenad Nešković, Gordana Kristek, Marija Milić, Hrvoje Vinković, Karlo Kedačić, Slavica Kvolik

Coagulation disorders in critically ill patients presenting with bleeding can be multicausal. The drugs applied can interfere and impair the coagulation cascade. Point-of-care (POC) coagulation assays may resolve difficult therapeutic situations in critical illness. We report on a 73-year-old critically ill male patient with massive hematuria after bladder lithotripsy. The patient was on low molecular weight heparin therapy due to recent pulmonary embolism. He was subjected to repeated surgical hemostasis which was ineffective despite massive transfusion protocol and normal standard coagulation profile. Additional POC coagulation assays were obtained and were indicative of platelet dysfunction. We revised his medical therapy and suspected the possible drug influence on platelet aggregation. After discontinuation of target drug, platelet aggregation increased whereas hematuria stopped. Coagulation disorders in intensive care unit patients are often multifactorial. Standard laboratory tests are unreliable in complex refractory bleeding and may result in inappropriate therapeutic decisions. Stepwise approach with assessment of clinical parameters, present therapy, and a combination of POC coagulation tests is the key to optimal therapeutic management.

危重病人出现出血的凝血功能障碍可能有多种原因。所用药物会干扰和损害凝血级联反应。护理点(POC)凝血检测可解决危重病人的治疗难题。我们报告了一名 73 岁男性重症患者在膀胱碎石术后出现大量血尿的病例。由于最近发生肺栓塞,患者正在接受低分子量肝素治疗。他曾多次接受手术止血,但尽管进行了大量输血,且标准凝血功能正常,但止血效果不佳。我们又进行了其他 POC 凝血检测,结果显示血小板功能障碍。我们修改了他的药物治疗方案,并怀疑可能是药物影响了血小板聚集。停用目标药物后,血小板聚集增加,而血尿症状却停止了。重症监护室患者的凝血功能障碍通常是多因素造成的。对于复杂的难治性出血,标准的实验室检测并不可靠,可能导致不恰当的治疗决策。通过评估临床参数、目前的治疗方法以及结合使用 POC 凝血检测,采取循序渐进的方法是优化治疗管理的关键。
{"title":"POINT-OF-CARE DIAGNOSTIC APPROACH IN A CRITICALLY ILL PATIENT WITH SEVERE BLEEDING FROM URINARY TRACT.","authors":"Sonja Škiljić, Nenad Nešković, Gordana Kristek, Marija Milić, Hrvoje Vinković, Karlo Kedačić, Slavica Kvolik","doi":"10.20471/acc.2023.62.s2.20","DOIUrl":"10.20471/acc.2023.62.s2.20","url":null,"abstract":"<p><p>Coagulation disorders in critically ill patients presenting with bleeding can be multicausal. The drugs applied can interfere and impair the coagulation cascade. Point-of-care (POC) coagulation assays may resolve difficult therapeutic situations in critical illness. We report on a 73-year-old critically ill male patient with massive hematuria after bladder lithotripsy. The patient was on low molecular weight heparin therapy due to recent pulmonary embolism. He was subjected to repeated surgical hemostasis which was ineffective despite massive transfusion protocol and normal standard coagulation profile. Additional POC coagulation assays were obtained and were indicative of platelet dysfunction. We revised his medical therapy and suspected the possible drug influence on platelet aggregation. After discontinuation of target drug, platelet aggregation increased whereas hematuria stopped. Coagulation disorders in intensive care unit patients are often multifactorial. Standard laboratory tests are unreliable in complex refractory bleeding and may result in inappropriate therapeutic decisions. Stepwise approach with assessment of clinical parameters, present therapy, and a combination of POC coagulation tests is the key to optimal therapeutic management.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"138-142"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
THE RELIABILITY OF URODYNAMIC ASSESSMENT IN CONFIRMATION OF STRESS URINARY INCONTINENCE IN RELATION TO BONNEY TEST. 在确认压力性尿失禁时,尿动力评估与邦尼测试的可靠性。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.1
Željko Blažinkov, Ines Krištofić, Ivan Jandrić, Mihaela Blažinkov, Boris Lovrić, Dragica Pavlović, Maja Čebohin, Slavko Marinić

According to the International Continence Society, stress (static) urinary incontinence is defined as any involuntary loss of urine on effort or physical exertion, due to which intravesical pressure overcomes urethral pressure, with no detrusor activity. Urodynamic testing accurately assesses the function of the bladder and urethra. The urodynamic assessment includes three tests: cystometry, uroflowmetry and profilometry (determination of urethral pressure profile). Prior to urodynamic assessment, it is mandatory to rule out urinary tract infection since it is an invasive test. Urethral profilometry is a technique that measures pressure in the urethra and bladder at rest, during stressful actions, and during the act of miction. Its main purpose is to evaluate the sphincter mechanism. During the examination, a special catheter is used, which is being slowly pulled out from the bladder neck throughout the urethra, with continuous recording of intraurethral pressure. In addition to measuring urethral pressures, stress urinary incontinence is also very successfully proven by the cough test and Bonney test. If, on forced cough, the urine escapes uncontrollably, and continence is restored by finger lifting the neck of the bladder, the diagnosis of static incontinence is confirmed. At our urogynecologic clinic, urodynamic examination is being routinely performed. In the present study, we included patients previously treated for urinary stress incontinence and compared their results of urodynamic assessment to the results of Bonney test. Of the 43 subjects in whom stress incontinence was proven with Bonney test, we recorded an appropriate profilometry result in 13 cases.

根据国际尿失禁协会(International Continence Society)的定义,压力性(静态)尿失禁是指膀胱内压超过尿道内压,在无逼尿肌活动的情况下,在用力或体力消耗时出现的任何不自主尿失禁。尿动力学检查可准确评估膀胱和尿道的功能。尿动力学评估包括三项测试:膀胱测量、尿流率测量和尿道压力曲线测量。在进行尿动力学评估之前,必须先排除尿路感染,因为这是一项侵入性检查。尿道压力剖面测量法是一种测量静息状态、紧张动作和排便时尿道和膀胱压力的技术。其主要目的是评估括约肌机制。在检查过程中,医生会使用一根特殊的导尿管,从膀胱颈部缓慢拉出导尿管至整个尿道,并持续记录尿道内的压力。除了测量尿道压力外,压力性尿失禁还可以通过咳嗽试验和邦尼试验来证明。如果用力咳嗽时,尿液不受控制地流出,用手指抬起膀胱颈即可恢复排尿,则可确诊为静态尿失禁。在我们的泌尿妇科诊所,尿动力检查是常规检查项目。在本研究中,我们纳入了曾接受过压力性尿失禁治疗的患者,并将他们的尿动力学评估结果与邦尼测试结果进行了比较。在 43 例经 Bonney 试验证实为压力性尿失禁的受试者中,我们记录了 13 例适当的轮廓测量结果。
{"title":"THE RELIABILITY OF URODYNAMIC ASSESSMENT IN CONFIRMATION OF STRESS URINARY INCONTINENCE IN RELATION TO BONNEY TEST.","authors":"Željko Blažinkov, Ines Krištofić, Ivan Jandrić, Mihaela Blažinkov, Boris Lovrić, Dragica Pavlović, Maja Čebohin, Slavko Marinić","doi":"10.20471/acc.2023.62.s2.1","DOIUrl":"10.20471/acc.2023.62.s2.1","url":null,"abstract":"<p><p>According to the International Continence Society, stress (static) urinary incontinence is defined as any involuntary loss of urine on effort or physical exertion, due to which intravesical pressure overcomes urethral pressure, with no detrusor activity. Urodynamic testing accurately assesses the function of the bladder and urethra. The urodynamic assessment includes three tests: cystometry, uroflowmetry and profilometry (determination of urethral pressure profile). Prior to urodynamic assessment, it is mandatory to rule out urinary tract infection since it is an invasive test. Urethral profilometry is a technique that measures pressure in the urethra and bladder at rest, during stressful actions, and during the act of miction. Its main purpose is to evaluate the sphincter mechanism. During the examination, a special catheter is used, which is being slowly pulled out from the bladder neck throughout the urethra, with continuous recording of intraurethral pressure. In addition to measuring urethral pressures, stress urinary incontinence is also very successfully proven by the cough test and Bonney test. If, on forced cough, the urine escapes uncontrollably, and continence is restored by finger lifting the neck of the bladder, the diagnosis of static incontinence is confirmed. At our urogynecologic clinic, urodynamic examination is being routinely performed. In the present study, we included patients previously treated for urinary stress incontinence and compared their results of urodynamic assessment to the results of Bonney test. Of the 43 subjects in whom stress incontinence was proven with Bonney test, we recorded an appropriate profilometry result in 13 cases.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"9-13"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER. 骨蛋白激酶是慢性肾病-矿物质和骨骼紊乱的早期征兆。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.7
Antun Gršković, Tanja Ćelić, Josip Španjol, Dean Markić, Bosiljka Devčić, Dragica Bobinac, Sanjin Rački

Chronic kidney disease (CKD) is among the most significant health problems, with the associated cardiovascular disease and bone metabolism disorders being the leading cause of morbidity and mortality in these patients. The aim of the study was to determine markers of bone turnover in patient sera (phosphates, calcium, alkaline phosphatase, parathyroid hormone and osteoprotegerin (OPG)) in all stages of kidney failure including kidney transplant recipients. We also wanted to determine whether dialysis vintage affects recovery of bone markers one year after transplantation. There were 164 study patients, whereas 30 healthy individuals served as a control group. Serum OPG progressively increased with decline of the glomerular filtration rate. The highest OPG concentration was recorded in dialysis group. We observed a statistically significant OPG increase in stage 2 CKD. In kidney transplant group, there was positive correlation between OPG and dialysis vintage. We also found that serum OPG was lower in patients treated with dialysis for less than 4 years prior to transplantation. We confirmed that CKD-mineral and bone disorder began in stage 3 CKD with parathyroid hormone and OPG elevation, and a statistically significant OPG increase in stage 2 CKD might be an early sign of CKD-mineral and bone disorder. Dialysis vintage longer than 4 years is associated with more significant disturbances in mineral and bone metabolism.

慢性肾脏病(CKD)是最重要的健康问题之一,与之相关的心血管疾病和骨代谢紊乱是这些患者发病和死亡的主要原因。这项研究的目的是确定包括肾移植受者在内的各阶段肾衰竭患者血清中的骨转换标志物(磷酸盐、钙、碱性磷酸酶、甲状旁腺激素和骨保护素(OPG))。我们还想确定透析年份是否会影响移植一年后骨标志物的恢复。研究对象包括 164 名患者,对照组为 30 名健康人。血清 OPG 随着肾小球滤过率的下降而逐渐增加。透析组的 OPG 浓度最高。我们观察到,在二期慢性肾脏病患者中,OPG 的增加具有统计学意义。在肾移植组中,OPG 与透析年份呈正相关。我们还发现,移植前接受透析治疗少于 4 年的患者血清 OPG 较低。我们证实,随着甲状旁腺激素和 OPG 的升高,慢性肾功能衰竭-矿物质和骨质紊乱从慢性肾功能衰竭 3 期开始,而在慢性肾功能衰竭 2 期,OPG 升高具有统计学意义,这可能是慢性肾功能衰竭-矿物质和骨质紊乱的早期征兆。透析时间超过4年的患者,其矿物质和骨代谢紊乱更为严重。
{"title":"OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.","authors":"Antun Gršković, Tanja Ćelić, Josip Španjol, Dean Markić, Bosiljka Devčić, Dragica Bobinac, Sanjin Rački","doi":"10.20471/acc.2023.62.s2.7","DOIUrl":"10.20471/acc.2023.62.s2.7","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is among the most significant health problems, with the associated cardiovascular disease and bone metabolism disorders being the leading cause of morbidity and mortality in these patients. The aim of the study was to determine markers of bone turnover in patient sera (phosphates, calcium, alkaline phosphatase, parathyroid hormone and osteoprotegerin (OPG)) in all stages of kidney failure including kidney transplant recipients. We also wanted to determine whether dialysis vintage affects recovery of bone markers one year after transplantation. There were 164 study patients, whereas 30 healthy individuals served as a control group. Serum OPG progressively increased with decline of the glomerular filtration rate. The highest OPG concentration was recorded in dialysis group. We observed a statistically significant OPG increase in stage 2 CKD. In kidney transplant group, there was positive correlation between OPG and dialysis vintage. We also found that serum OPG was lower in patients treated with dialysis for less than 4 years prior to transplantation. We confirmed that CKD-mineral and bone disorder began in stage 3 CKD with parathyroid hormone and OPG elevation, and a statistically significant OPG increase in stage 2 CKD might be an early sign of CKD-mineral and bone disorder. Dialysis vintage longer than 4 years is associated with more significant disturbances in mineral and bone metabolism.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"46-52"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
UROTHELIAL CARCINOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN CROATIA - A SINGLE-CENTER STUDY. 克罗地亚科维德-19 大流行之前和期间的尿路癌--一项单中心研究。
IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-07-01 DOI: 10.20471/acc.2023.62.s2.5
Marin Glavčić, Ivona Ćudina, Pero Hrabač, Goran Glavčić, Marijana Ćorić

The aim of this study was to compare the number of newly diagnosed, histopathologically confirmed cases of urothelial carcinoma before and during the COVID-19 pandemic at the Zagreb University Hospital Center. We retroactively collected and analyzed 300 histopathologically confirmed urothelial carcinoma between January 1, 2019, and December 31, 2020, at the Department of Pathology and Cytology, Zagreb University Hospital Center. Our results showed that during the COVID-19 pandemic, there was a statistically significant decrease (p=0.001; χ2-test) in the number of newly diagnosed, histopathologically confirmed cases of urothelial carcinoma at the Zagreb University Hospital Center. There was a decrease in the absolute number of newly diagnosed urothelial carcinoma by 25.8% in the observed time of the pandemic (March 19, 2020 to December 31, 2020) as compared to the same period of the previous year (March 19, 2019 to December 31, 2019). Our study is the first study of this type based on the number of newly diagnosed urothelial carcinoma in Croatia. Observing the early period of the pandemic, our results provide important foundation for future monitoring and long-term consequences of the pandemic on the morbidity and mortality of urothelial carcinoma.

本研究旨在比较萨格勒布大学医院中心在 COVID-19 大流行之前和期间新诊断的、经组织病理学确诊的尿路上皮癌病例数量。我们追溯收集并分析了萨格勒布大学医院中心病理学和细胞学部在2019年1月1日至2020年12月31日期间经组织病理学确诊的300例尿路癌病例。我们的研究结果表明,在 COVID-19 大流行期间,萨格勒布大学医院中心新诊断的组织病理学确诊的尿路癌病例数出现了统计学意义上的显著下降(P=0.001;χ2 检验)。与上一年同期(2019 年 3 月 19 日至 2019 年 12 月 31 日)相比,大流行期间(2020 年 3 月 19 日至 2020 年 12 月 31 日)新诊断出的尿路癌绝对数量减少了 25.8%。我们的研究是首个基于克罗地亚新诊断尿路癌数量的此类研究。通过观察疫情初期的情况,我们的研究结果为今后监测疫情以及疫情对尿路癌发病率和死亡率的长期影响提供了重要依据。
{"title":"UROTHELIAL CARCINOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN CROATIA - A SINGLE-CENTER STUDY.","authors":"Marin Glavčić, Ivona Ćudina, Pero Hrabač, Goran Glavčić, Marijana Ćorić","doi":"10.20471/acc.2023.62.s2.5","DOIUrl":"10.20471/acc.2023.62.s2.5","url":null,"abstract":"<p><p>The aim of this study was to compare the number of newly diagnosed, histopathologically confirmed cases of urothelial carcinoma before and during the COVID-19 pandemic at the Zagreb University Hospital Center. We retroactively collected and analyzed 300 histopathologically confirmed urothelial carcinoma between January 1, 2019, and December 31, 2020, at the Department of Pathology and Cytology, Zagreb University Hospital Center. Our results showed that during the COVID-19 pandemic, there was a statistically significant decrease (p=0.001; χ2-test) in the number of newly diagnosed, histopathologically confirmed cases of urothelial carcinoma at the Zagreb University Hospital Center. There was a decrease in the absolute number of newly diagnosed urothelial carcinoma by 25.8% in the observed time of the pandemic (March 19, 2020 to December 31, 2020) as compared to the same period of the previous year (March 19, 2019 to December 31, 2019). Our study is the first study of this type based on the number of newly diagnosed urothelial carcinoma in Croatia. Observing the early period of the pandemic, our results provide important foundation for future monitoring and long-term consequences of the pandemic on the morbidity and mortality of urothelial carcinoma.</p>","PeriodicalId":7072,"journal":{"name":"Acta clinica Croatica","volume":"62 Suppl2","pages":"33-36"},"PeriodicalIF":0.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta clinica Croatica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1